“Magnolia’s Guide to Adventuring” is housed on Acadia’s “Rett Revealed” website, which went live in late 2022 as part of a ...
Novo Holdings has made another investment in biopharma manufacturing, as its key portfolio company, Novo Nordisk, looks to ...
Two years ago, when Merck KGaA restructured, forming a new life science business, the goal was to maximize the enticing ...
The next Mindy Kaling project? Advocating for people with plaque psoriasis. | The next Mindy Kaling project? Advocating for ...
Reflecting on Eisai’s Alzheimer’s disease development journey—from Aricept’s U.S. | Eisai has laid out an ambitious goal to ...
Merck’s cancer drug giant Keytruda has helped the Big Pharma top how oncologists see cancer drugmakers, but no one company is ...
Thirty seconds. That’s the sweet spot for pharma ads on connected TV. Ad tech company Innovid made the discovery in an ...
After Eli Lilly sued several companies that were allegedly selling unauthorized versions of its tirzepatide products, the drugmaker has successfully cracked down on one of them. | Under legal pressure ...
After suffering a setback with U.S. regulators last month, Eisai and Biogen’s effort to deploy a more convenient version of ...
It’s been a long wait for Ascendis Pharma to score FDA approval for its hormone replacement therapy TransCon PTH ...
Clinical trial names span a broad range, from straightforward acronyms to more inspiring titles—see: Eli Lilly’s ...
Eugia remains under FDA scrutiny as the unit of Indian drugmaker Aurobindo has received its fifth Form 483 since December.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results